Diagnostic and intraoperative immunoscintigraphy in ovarian cancer

Gitsch, E; Pateisky, N.; Schatten, Ch.

doi:10.1016/0028-2243(89)90124-x

Cited by 4 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No data are available on radioguided SLN biopsy for ovarian cancer. However, RIGS [ 149 , 575 - 582 ] and 18 F-FDG-directed surgery [ 45 , 53 , 583 ] applications of the gamma detection probe have been investigated.…”

Section: Clinical Applications (Table 2 )mentioning

confidence: 99%

“…Since first described for ovarian cancer by Martin et al in 1988 [ 149 , 578 ], the feasibility of RIGS has been evaluated by several groups of investigators [ 149 , 575 - 582 ]. The focus of all these RIGS protocols has been the detection of occult recurrence in those ovarian cancer patients undergoing both second look laparotomy and those undergoing surgery for suspected or confirmed recurrence.…”

Section: Clinical Applications (Table 2 )mentioning

confidence: 99%

“…Martin et al [ 149 , 578 ] evaluated 125 I-B72.3 murine monoclonal antibody, McIntosh et al [ 582 ] evaluated 125 I-CC49 murine monoclonal antibody, and Krag et al [ 580 ] evaluated 111 I-B72.3 murine monoclonal antibody. Gitsch et al [ 575 - 577 ] and Jäger et al [ 579 ] evaluated 131 I-OC125 (anti-CA125) murine monoclonal antibody. Finally, Ind et al [ 581 ] evaluated 99m Tc labeled murine monoclonal antibodies SM3 and H17E2.…”

Section: Clinical Applications (Table 2 )mentioning

confidence: 99%

“…Finally, Ind et al [ 581 ] evaluated 99m Tc labeled murine monoclonal antibodies SM3 and H17E2. Each of these RIGS protocols utilized similar regimens with intravenous injection of 2 to 5 mCi (74 to 185 MBq) of the radiolabeled monoclonal antibody at an interval of 4 to 42 days prior to the planned surgical procedure [ 149 , 575 - 582 ]. The reported detection rates for RIGS in these reports ranged from 50% to 80%.…”

Section: Clinical Applications (Table 2 )mentioning

confidence: 99%

See 3 more Smart Citations

A comprehensive overview of radioguided surgery using gamma detection probe technology

et al. 2009

View full text Add to dashboard Cite

The concept of radioguided surgery, which was first developed some 60 years ago, involves the use of a radiation detection probe system for the intraoperative detection of radionuclides. The use of gamma detection probe technology in radioguided surgery has tremendously expanded and has evolved into what is now considered an established discipline within the practice of surgery, revolutionizing the surgical management of many malignancies, including breast cancer, melanoma, and colorectal cancer, as well as the surgical management of parathyroid disease. The impact of radioguided surgery on the surgical management of cancer patients includes providing vital and realtime information to the surgeon regarding the location and extent of disease, as well as regarding the assessment of surgical resection margins. Additionally, it has allowed the surgeon to minimize the surgical invasiveness of many diagnostic and therapeutic procedures, while still maintaining maximum benefit to the cancer patient. In the current review, we have attempted to comprehensively evaluate the history, technical aspects, and clinical applications of radioguided surgery using gamma detection probe technology.

show abstract

Section: Clinical Applications (Table 2 )mentioning

confidence: 99%

Section: Clinical Applications (Table 2 )mentioning

confidence: 99%

Section: Clinical Applications (Table 2 )mentioning

confidence: 99%

Section: Clinical Applications (Table 2 )mentioning

confidence: 99%

See 2 more Smart Citations

A comprehensive overview of radioguided surgery using gamma detection probe technology

et al. 2009

View full text Add to dashboard Cite

show abstract

Radioimmunoguided Surgery: Intraoperative Radioimmunodetection for the Radioguided Localization and Resection of Tumors

Povoski

Mojzisik

Sullivan

2016

Radioguided Surgery

View full text Add to dashboard Cite

Radioimmunoscintigraphy of ovarian tumours with technetium-99m labelled monoclonal antibody-170: first clinical experiences

et al. 1995

View full text Add to dashboard Cite

The recently developed technetium-99m-labelled monoclonal antibody-170 (MAb-170) was designed for diagnostic use in patients suffering from gynaecological adenocarcinoma. Following in vitro studies which showed immunoreactivity of this antibody to more than 90% of human adenocarcinomas, the present investigation was initiated to verify its usefulness for radioimmunoscintigraphy of ovarian tumours. Most of the 30 patients participating in this study underwent immunoscintigraphy prior to first-look surgery. Biokinetic evaluation in two patients showed a plasma half-time of 18.9 h (mean value, n = 2, r = 0.98) and a biexponential total body curve with values of 7.7 h and 17 days (r = 0.98). The mean 24-h urinary excretion was 12% of the injected dose. Radioimmunoscintigraphy using the MAb-170 recognised 12 of 13 cases of adenocarcinoma of the ovaries, corresponding to an overall sensitivity of 92.3%. Specificity was 94.1% (16/17). The calculation of accuracy yielded a figure of 93.3% (28/30). Of 33 known lesions, 26 were visualised successfully; thus the locoregional sensitivity was 78.8%. Of 29 benign tumour sites, 28 showed no evidence of tracer accumulation, corresponding to a locoregional specificity of 96.6%. The smallest lesion visualised was an adenocarcinoma of the corpus uteri with a diameter of 1.5 cm. Technetium-99m labelled MAb-170 is a promising new radiopharmaceutical for immunoscintigraphy of ovarian adenocarcinoma.

show abstract

Diagnostic and intraoperative immunoscintigraphy in ovarian cancer

Cited by 4 publications

References 6 publications

A comprehensive overview of radioguided surgery using gamma detection probe technology

A comprehensive overview of radioguided surgery using gamma detection probe technology

Radioimmunoguided Surgery: Intraoperative Radioimmunodetection for the Radioguided Localization and Resection of Tumors

Radioimmunoscintigraphy of ovarian tumours with technetium-99m labelled monoclonal antibody-170: first clinical experiences

Contact Info

Product

Resources

About